"Vaxon develops innovative immuno-therapeutic products to treat cancer"

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative drugs for the treatment of malignancies, including prostate, lung, breast, renal, liver and colon cancer. The company is based on an original discovery made by Dr. Kostas Kosmatopoulos and his team : optimized cryptic peptides.

Vaxon Biotech's products are intended to treat existing cancers (therapeutic vaccines) by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. These vaccines target antigens, overexpressed in tumor cells but present in very low quantities in normal cells.

The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors. Vx-001 completed phase I clinical trial and showed good tolerance and immune response. This treatment also showed extended patient survival and induced lengthy disease stabilization, in about 60% of the patients who completed the protocol. Vx-001 is due to enter controlled phase IIb in non small cell lung cancer, and in phase IIb in hepatocellular cancer. Vx-006 should also enter phase I/II clinical development.